Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccinia Immune Globulin (Human)
- Development stage
- Unknown
- Lead developer
- Emergent BioSolutions
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Vaccinia Immune Globulin (VIG) is a biologic therapeutic consisting of purified human immunoglobulin G (IgG) derived from the pooled plasma of individuals who have been immunized with the vaccinia (smallpox) vaccine. It serves as a passive immunotherapeutic agent, providing immediate neutralizing antibodies against the vaccinia virus and other orthopoxviruses. In the context of NIAID-sponsored research, this specific intramuscular formulation was utilized as an investigational new drug (IND) to manage severe complications of vaccinia vaccination—such as progressive vaccinia, eczema vaccinatum, and generalized vaccinia—or accidental exposures occurring during HIV vaccine trials that employed vaccinia virus vectors. The treatment aims to neutralize viral particles and facilitate their clearance from the body.
- Other names
- Vaccinia Immune GlobulinVIGIMHuman Vaccinia Immune Globulin
02
Targets
OPXV MV/EEV antigens (Orthopoxvirus mature virion and extracellular enveloped virion surface antigens)
Beyond the preview
Go deeper on Vaccinia Immune Globulin (Human).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaccinia Immune Globulin (Human).